Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance therapy with pyrotinib or dalpiciclib after T-DXh in HER2+ MBC
NCT07179939Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Sep 2025
- Primary completion
- Dec 2030
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan, pyrotinib, dalpiciclib in HER2-positive breast cancer, sponsored by Fudan University. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
trastuzumab rezetecanpyrotinibdalpiciclib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT07179939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07179939.